<p>生物科技股票可能是投資者感興趣的一個領域。它們可以在臨牀試驗或 FDA 批准方面的積極消息後帶來巨大收益。然而，如果公司的治療方案出現不利消息或未達預期，也可能導致股價大幅下跌。</p>
<p>在我看來，當投資生物科技行業時，最好避開那些更容易出現股價劇烈波動的小公司。最好選擇那些提供多種治療方案並具有增長潛力的大公司。</p>
<p>在選擇當前要購買的生物科技股票時，我選擇了那些在過去一年中股價大幅上漲且估值合理的公司，其前瞻市盈率與整個行業相比較低。</p>
<h2>聯合治療（UTHR）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：viewimage / Shutterstock.com</p>
<p><strong>聯合治療</strong>（納斯達克股票代碼：<strong>UTHR</strong>）主要生產和銷售與肺部相關的危及生命的疾病的治療方案，如肺動脈高壓。其產品包括 Tyvaso、Remodulin、Adcirca 和 Orenitram。</p>
<p>過去一年，由於其第一季度業績超出預期，其股價上漲了 40%。</p>
<p>5 月 1 日，聯合治療公佈了 2024 年第一季度的財報，稱總收入同比增長 34%，淨利潤同比增長 27%。其旗艦治療方案中有四種報告顯示年度銷售增長達兩位數。</p>
<p>UTHR 的估值合理，前瞻市盈率為 12.73，而行業中位數前瞻市盈率為 19.61。</p>
<p>由於其多種治療方案的強勁銷售增長，UTHR 為投資者提供上漲潛力。</p>
<h2><strong>奧洛茲美醫療</strong>（HALO）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Microgen / Shutterstock</p>
<p><strong>奧洛茲美醫療</strong>（納斯達克股票代碼：<strong>HALO</strong>）經營一家提供皮下藥物遞送解決方案以及其他專有酶相關產品的醫療科技平台。</p>
<p>5 月 7 日，奧洛茲美醫療公佈了 2024 年第一季度的財報，稱總收入同比增長 21%，淨利潤增長 94%。它還宣佈了一項限額為 7.5 億美元的股票回購計劃。</p>
<p>6 月，HALO 更新了其 2024 年全年指導預期，稱預期總收入介於 9.35 億美元至 10.15 億美元之間。此次指導更新是在其產品 Enhanze 獲得專利批准後發佈的。</p>
<p>奧洛茲美醫療的前瞻市盈率為 13.34，而行業平均值為 19.61。</p>
<p>HALO 將是投資組合的極佳選擇。特別是在最近獲得專利批准和提高預期後，它提供了增長潛力。</p>
<h2>安進（AMGN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p><strong>安進</strong>（納斯達克股票代碼：<strong>AMGN</strong>）是一家生產治療方案的製藥公司，其產品包括 Enbrel、Otezla、Prolia、Xgeva 和 Repatha，用於治療諸如牛皮癬、預防心臟病發作和骨質疏鬆症等多種問題。它還與其他醫療公司合作開發和銷售治療方案。</p>
<p>在過去一年中，由於其強勁的第一季度業績報告，其股價上漲了 47%。</p>
<p>5 月 2 日，安進公佈了 2024 年第一季度的財報。報告顯示，總收入增長 22%，其多款產品的年度銷售增長超過兩位數，淨利潤與前一年基本持平。</p>
<p>其股價在其關於潛在減肥藥物 MariTide 的正面數據的第一季度業績報告後大約上漲了 12%。</p>
<p>安進在多款治療方案中報告了可觀的銷售增長，預計 2024 年全年總收入將介於 325 億美元至 338 億美元之間。對於投資者來説，它是一個穩健的選擇；它是一家強勁的生物科技股票，尤其是從長期來看，可以為投資者帶來增加的回報。</p>
<p>安進的估值也相當合理。其前瞻市盈率為 16.97，而行業平均值為 19.61。</p>
<p><em>在發佈日期，負責編輯在本文中未持有（直接或間接）任何提到的證券。</em></p>
<p><em>截至目前，Noah Bolton 在本文提到的證券中未持有（直接或間接）任何頭寸。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</em></p>
<p>Noah 擁有約一年的自由撰稿經驗。他曾與 Investopedia 合作，涉及股市和財經新聞等主題。</p>
<p>生物科技、醫療保健</p>

聯合治療

奧洛茲美醫療

<p>三家生物科技股票可供投資考慮：聯合治療 (UTHR)，奧洛茲美醫療 (HALO) 和安進 (AMGN)。這些公司股價增長強勁，盈利報告積極，並具有增加回報的潛力。建議關注生物科技行業中規模較大的公司，以獲得穩定性和增長潛力。這些股票為該領域的投資者提供了機會</p>

<p>Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals. However, they may also cause large share price drops following bad news or missed expectations surrounding a company’s treatments.</p>
<div class="lb-trans"><p>生物科技股票可能是投資者感興趣的一個領域。它們可以在臨牀試驗或 FDA 批准方面的積極消息後帶來巨大收益。然而，如果公司的治療方案出現不利消息或未達預期，也可能導致股價大幅下跌。</p>
</div><p>In my opinion, when investing in the biotech industry, it’s best to steer clear of smaller companies that are more susceptible to wild swings in their share price. It is much better to stick with larger companies that offer a wide array of treatments and increased growth potential.</p>
<div class="lb-trans"><p>在我看來，當投資生物科技行業時，最好避開那些更容易出現股價劇烈波動的小公司。最好選擇那些提供多種治療方案並具有增長潛力的大公司。</p>
</div><p>When choosing which biotech stocks to buy right now, I settled on companies that have experienced strong share price appreciation over this past year and a fair valuation, with a low forward P/E ratio compared to the sector overall.</p>
<div class="lb-trans"><p>在選擇當前要購買的生物科技股票時，我選擇了那些在過去一年中股價大幅上漲且估值合理的公司，其前瞻市盈率與整個行業相比較低。</p>
</div><h2>United Therapeutics (UTHR)</h2>
<div class="lb-trans"><h2>聯合治療（UTHR）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: viewimage / Shutterstock.com</p>
<div class="lb-trans"><p>來源：viewimage / Shutterstock.com</p>
</div><p><strong>United Therapeutics</strong>(NASDAQ: <strong>UTHR</strong>) manufactures and commercializes treatments for life-threatening diseases primarily related to the lungs, such as pulmonary hypertension. Its products include Tyvaso, Remodulin, Adcirca, and Orenitram.</p>
<div class="lb-trans"><p><strong>聯合治療</strong>（納斯達克股票代碼：<strong>UTHR</strong>）主要生產和銷售與肺部相關的危及生命的疾病的治療方案，如肺動脈高壓。其產品包括 Tyvaso、Remodulin、Adcirca 和 Orenitram。</p>
</div><p>Over the past year, its share price has increased by 40%, primarily due to its first-quarter earnings beat.</p>
<div class="lb-trans"><p>過去一年，由於其第一季度業績超出預期，其股價上漲了 40%。</p>
</div><p>On May 1, United Therapeutics reported earnings for the first quarter of 2024, stating that total revenue increased by 34% and net income rose by 27% compared to the previous year. Four of its flagship treatments reported double-digit sales growth year over year.</p>
<div class="lb-trans"><p>5 月 1 日，聯合治療公佈了 2024 年第一季度的財報，稱總收入同比增長 34%，淨利潤同比增長 27%。其旗艦治療方案中有四種報告顯示年度銷售增長達兩位數。</p>
</div><p>UTHR is trading at a fair valuation, with a forward P/E ratio of 12.73, compared to the median sector forward P/E ratio of 19.61.</p>
<div class="lb-trans"><p>UTHR 的估值合理，前瞻市盈率為 12.73，而行業中位數前瞻市盈率為 19.61。</p>
</div><p>UTHR offers investors upside potential due to its strong sales growth among many of its treatments.</p>
<div class="lb-trans"><p>由於其多種治療方案的強勁銷售增長，UTHR 為投資者提供上漲潛力。</p>
</div><h2><strong>Halozyme Therapeutics</strong>(HALO)</h2>
<div class="lb-trans"><h2><strong>奧洛茲美醫療</strong>（HALO）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Microgen / Shutterstock</p>
<div class="lb-trans"><p>來源：Microgen / Shutterstock</p>
</div><p><strong>Halozyme Therapeutics</strong> (NASDAQ: <strong>HALO</strong>) operates a healthcare tech platform that provides subcutaneous drug delivery solutions along with other commercialized products related to proprietary enzymes.</p>
<div class="lb-trans"><p><strong>奧洛茲美醫療</strong>（納斯達克股票代碼：<strong>HALO</strong>）經營一家提供皮下藥物遞送解決方案以及其他專有酶相關產品的醫療科技平台。</p>
</div><p>On May 7, Halozyme reported earnings for the first quarter of 2024, stating that total revenue increased by 21% and net income rose by 94%. It also announced a share buyback program with a limit of $750 million in repurchases.</p>
<div class="lb-trans"><p>5 月 7 日，奧洛茲美醫療公佈了 2024 年第一季度的財報，稱總收入同比增長 21%，淨利潤增長 94%。它還宣佈了一項限額為 7.5 億美元的股票回購計劃。</p>
</div><p>In June, HALO updated its full-year guidance for 2024, stating that expected total revenue is between $935 million and $1,015 million. This update in guidance comes after the patent approval regarding its product Enhanze.</p>
<div class="lb-trans"><p>6 月，HALO 更新了其 2024 年全年指導預期，稱預期總收入介於 9.35 億美元至 10.15 億美元之間。此次指導更新是在其產品 Enhanze 獲得專利批准後發佈的。</p>
</div><p>Halozyme is trading at a forward P/E ratio of 13.34, while the sector average is 19.61.</p>
<div class="lb-trans"><p>奧洛茲美醫療的前瞻市盈率為 13.34，而行業平均值為 19.61。</p>
</div><p>HALO would be a great addition to an investment portfolio. It offers growth potential, especially following the recent patent approval and raised guidance.</p>
<div class="lb-trans"><p>HALO 將是投資組合的極佳選擇。特別是在最近獲得專利批准和提高預期後，它提供了增長潛力。</p>
</div><h2>Amgen (AMGN)</h2>
<div class="lb-trans"><h2>安進（AMGN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p><strong>Amgen</strong> (NASDAQ: <strong>AMGN</strong>) is a therapeutics manufacturer with products such as Enbrel, Otezla, Prolia, Xgeva, and Repatha, which treat a number of issues such as psoriasis, heart attack prevention, and osteoporosis. It also collaborates with other healthcare companies to develop and commercialize treatments.</p>
<div class="lb-trans"><p><strong>安進</strong>（納斯達克股票代碼：<strong>AMGN</strong>）是一家生產治療方案的製藥公司，其產品包括 Enbrel、Otezla、Prolia、Xgeva 和 Repatha，用於治療諸如牛皮癬、預防心臟病發作和骨質疏鬆症等多種問題。它還與其他醫療公司合作開發和銷售治療方案。</p>
</div><p>Over this past year, its share price has risen by 47%, partly due to its strong first-quarter earnings report.</p>
<div class="lb-trans"><p>在過去一年中，由於其強勁的第一季度業績報告，其股價上漲了 47%。</p>
</div><p>On May 2, Amgen reported its earnings for the first quarter of 2024. It stated that total revenue increased by 22%, several of its products reported year-over-year sales growth above double-digits, and its net income remained practically unchanged compared to the year before.</p>
<div class="lb-trans"><p>5 月 2 日，安進公佈了 2024 年第一季度的財報。報告顯示，總收入增長 22%，其多款產品的年度銷售增長超過兩位數，淨利潤與前一年基本持平。</p>
</div><p>Its stock price surged by roughly 12% following its first-quarter earnings report in which it confirmed positive data about its potential weight loss drug MariTide.</p>
<div class="lb-trans"><p>其股價在其關於潛在減肥藥物 MariTide 的正面數據的第一季度業績報告後大約上漲了 12%。</p>
</div><p>Amgen has reported decent sales growth among several treatments, and total revenue for the full year 2024 is expected to be between $32. 5 billion and $33.8 billion. It is a solid choice for investors; it is a robust biotech stock that can offer investors increased returns, especially over the long term.</p>
<div class="lb-trans"><p>安進在多款治療方案中報告了可觀的銷售增長，預計 2024 年全年總收入將介於 325 億美元至 338 億美元之間。對於投資者來説，它是一個穩健的選擇；它是一家強勁的生物科技股票，尤其是從長期來看，可以為投資者帶來增加的回報。</p>
</div><p>Amgen is also trading at a decent valuation. Its forward P/E ratio is 16.97, while the sector average is 19.61.</p>
<div class="lb-trans"><p>安進的估值也相當合理。其前瞻市盈率為 16.97，而行業平均值為 19.61。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在發佈日期，負責編輯在本文中未持有（直接或間接）任何提到的證券。</em></p>
</div><p><em>As of this writing, Noah Bolton did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>截至目前，Noah Bolton 在本文提到的證券中未持有（直接或間接）任何頭寸。本文中表達的觀點屬於作者個人，遵守 InvestorPlace.com 的發佈準則。</em></p>
</div><p>Noah has about a year of freelance writing experience. He’s worked with Investopedia dealing with topics such as the stock market and financial news.</p>
<div class="lb-trans"><p>Noah 擁有約一年的自由撰稿經驗。他曾與 Investopedia 合作，涉及股市和財經新聞等主題。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物科技、醫療保健</p>
</div>

第三季度推薦購買的三隻生物科技股票